MYCOPHENOLATEMOFETIL FOR IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: A FOLLOW‐UP STUDY OF 191 PATIENTS

Background. Mycophenolatemofetil (MMF) combined with calcineurin inhibitors (CNIs) as immunosuppression after orthotopic liver transplantation (OLT) is still under discussion. We retrospectively investigated the immunosuppressive potency of MMF for treatment of steroid‐resistant acute rejection (AR) or chronic rejection (CR), chronic graft dysfunction, and CNI‐induced toxicity in patients after OLT. Methods. Between 1988 and 2001 we performed 1,386 OLTs in 1,258 patients. Since 1995, 191 patients have received MMF after OLT for steroid‐resistant AR or CR, chronic graft dysfunction (115 patients), and CNIinduced toxicity (76 patients). The mean follow‐up time was 56 months. Results. Of 47 patients with steroid‐resistant AR, 12 had been treated with OKT3, without resolving the rejection. Overall, bilirubin and transaminases decreased significantly within 2 weeks after the addition of MMF, and liver function normalized in 38 patients. Five of eight patients with CR demonstrated stable liver function after a follow‐up of 55±8 months; 52 of 60 patients with chronic graft dysfunction improved within 3 months; and 46 of 59 patients with CNI‐induced nephrotoxicity improved after MMF treatment and a reduction of CNIs (with a significant decrease in serum creatinine within 2 weeks and an increase of creatinine clearance within 3 months). Clinical symptoms improved in 10 of 12 patients with neurotoxicity and four of five patients with hepatotoxicity. Side effects of MMF, such as gastrointestinal disorders or bone marrow toxicity, occurred in 60 patients (31.4%). The incidence of infections did not increase. Patient survival was 93%, and graft survival was 88.2%. Conclusions. MMF is a potent and safe immunosuppressive agent in OLT recipients for rescue therapy in AR, CR, or chronic graft dysfunction and helps to reduce the serious toxic side effects of CNIs.

[1]  J. Prieto,et al.  Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  U. Settmacher,et al.  Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. , 1999, Transplantation proceedings.

[3]  G. Tufveson,et al.  Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. , 1999, Transplantation.

[4]  D. Eckhoff,et al.  RS-61443--a new, potent immunosuppressive agent. , 1991, Transplantation.

[5]  A. Allison,et al.  Mycophenolate mofetil and its mechanisms of action. , 2000, Immunopharmacology.

[6]  F. Cigarroa,et al.  Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. , 1998, Transplantation proceedings.

[7]  J. Rosete,et al.  Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  W. Bechstein,et al.  Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. , 1995, Transplantation.

[9]  D. Elbourne,et al.  Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial , 2002, The Lancet.

[10]  M. Manns,et al.  Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study , 2001, The Lancet.

[11]  D. Paterson,et al.  Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. , 1998, Transplantation.

[12]  J. Contreras,et al.  Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. , 1998, Transplantation.

[13]  S. McDiarmid.  Mycophenolate mofetil in liver transplantation. , 1996, Clinical transplantation.

[14]  D. Renlund,et al.  A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. , 1998, Transplantation.

[15]  W. Bechstein,et al.  Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506‐treated patients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  M. Manns,et al.  Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. , 2000, Transplantation.

[17]  G. Berry,et al.  Treatment by Mycophenolate Mofetil of Advanced Graft Vascular Disease in Non‐Human Primate Recipients of Orthotopic Aortic Allografts , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  J. Emond,et al.  Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. , 1999, Transplantation.

[19]  P. Halloran,et al.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. , 1997, Transplantation.

[20]  P. Neuhaus,et al.  FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. , 1997, Transplantation proceedings.

[21]  T. Mathew.  A Blinded, Long-term, Randomized Multicenter Study Of Mycophenolate Mofetil In Cadaveric Renal Transplantation: Results at Three Years1,2 , 1998 .

[22]  M. Hudson,et al.  Mycophenolate mofetil monotherapy in liver transplantation , 2001, The Lancet.

[23]  W. Bechstein,et al.  Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. , 1994, Transplantation.

[24]  M. Myllärniemi,et al.  Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. , 1995, Transplant immunology.

[25]  W. Bechstein,et al.  Neurotoxicity after orthotopic liver transplantation in cyclosporin A‐and FK 506‐treated patients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[26]  W. Bechstein,et al.  Mycophenolate mofetil added to immunosuppression after liver transplantation – first results , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[27]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[28]  G. Klintmalm,et al.  A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[30]  A. Tsaroucha,et al.  Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. , 1997, Transplantation proceedings.

[31]  V. Dzau,et al.  Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. , 1995, Transplantation.